lung cancer
It joins Lunit and Us2.ai in the vendor-neutral, cloud-based marketplace of medical AI solutions.
Researchers claim their invention offers a cost-effective and faster way to do single-cell analysis.
The approval marks its entry into the $160-billion US medical device market.
Also, Lunit signed multiple contracts this week to deliver its AI imaging software in Hong Kong, Mongolia, and Brazil.
Also, Babylon GP at Hand opens two new clinics in London.